UNSPSC 51141581: Taltrimide

This classification denotes an anticonvulsant agent with the molecular formula C13H16N2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NQ74U9QR5D, chemically known as 2h-isoindole-2-ethanesulfonamide, 1,3-dihydro-n-(1-methylethyl)-1,3-dioxo- but generally known as taltrimide, which bears US NIH Compound Identifier 71248. European Medicines Agency schedules Taltrimide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10817MIG.

UNSPSC 51141581 Taltrimide is a Commodity code that in state and local practice covers pharmaceutical products and related drug-management systems rather than taltrimide specifically — recent solicitations show state and local agencies buying naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through both direct purchase and cooperative purchasing arrangements. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). Work under the code includes procurement of finished pharmaceutical products with specified National Drug Codes, quarterly delivery of emergency response medications, and establishment of direct-to-manufacturer prescription programs that bypass traditional pharmacy benefit managers and group purchasing organizations.

Geographic activity centers on Florida, Texas, and the MMCAP region (Minnesota and participating states including Oregon). Representative recent opportunities include Seminole County's IFB60459723LAS, an Invitation for Bid (IFB) posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; the Texas Health and Human Services Commission's Request for Information (RFI) HHS0017013, posted April 3, 2026, soliciting vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's RFP S1070000015802, posted January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers and distributed across multiple state and local facilities. Vendors pursuing these opportunities must maintain FDA compliance, cGMP certification, Drug Supply Chain Security Act adherence, comprehensive insurance coverage, and E-Verify authorization; contracts typically include two-year initial terms with renewal options.